Comparison · NCT00255840-sae
Antiretroviral Therapy Monitored by Medical Officer vs Antiretroviral Therapy Managed by Primary Health Care Nurse: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Antiretroviral Therapy Monitored by Medical Officer vs Antiretroviral Therapy Managed by Primary Health Care Nurse: serious adverse events. Trial comparisons, record NCT00255840-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00255840-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.309 | 0.266 | 0.355 | wilson | |
| Risk in group 2 | 0.379 | 0.333 | 0.427 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0699 | -0.134 | -0.00456 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.815 | 0.673 | 0.988 | log | |
| Odds ratio, group 1 over group 2 | 0.733 | 0.548 | 0.98 | log | |
Number needed to treat, for one fewer participant with a serious adverse event on Antiretroviral Therapy Monitored by Medical Officer than on Antiretroviral Therapy Managed by Primary Health Care Nurse | 14.3 | 7.44 | 219 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Antiretroviral Therapy Monitored by Medical Officer | First line antiretroviral regimen monitored by a HIV-trained medical doctor:~1. Stavudine (\>60 kg: 40 mg twice daily and \<60 kg: 30 mg twice daily)~2. Lamivudine (150mg twice daily) and~3. Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count \<250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count \> 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily). | 126 | 408 | EG000 |
| Group 2 | Antiretroviral Therapy Managed by Primary Health Care Nurse | First line antiretroviral regimen monitored by HIV-trained primary health care nurse:~1. Stavudine (\>60 kg: 40 mg twice daily and \<60 kg: 30 mg twice daily)~2. Lamivudine (150mg twice daily) and~3. Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count \<250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count \> 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily). | 153 | 404 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities
- NCT number
- NCT00255840
- Phases
- NA
- Conditions
- HIV Infections
- Interventions
- Monitoring by an HIV-trained medical doctor, Monitoring by an HIV-trained primary care nurse, Efavirenz, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine
- Lead sponsor
- CIPRA SA
- Results first posted
- 2011-06-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00255840?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00255840-sae